

Anke H Maitland-Van Der Zee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2592950/publications.pdf>

Version: 2024-02-01

280
papers

12,346
citations

50276

46
h-index

33894

99
g-index

296
all docs

296
docs citations

296
times ranked

17920
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. <i>Lancet, The</i> , 2012, 380, 572-580.	13.7	1,937
2	Pharmacogenetics: From Bench to Byte” An Update of Guidelines. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 662-673.	4.7	869
3	A Randomized Trial of Genotype-Guided Dosing of Warfarin. <i>New England Journal of Medicine</i> , 2013, 369, 2294-2303.	27.0	735
4	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	13.7	562
5	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. <i>BMJ, The</i> , 2014, 349, g4164-g4164.	6.0	528
6	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology, the</i> , 2017, 5, 97-105.	11.4	298
7	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. <i>American Journal of Human Genetics</i> , 2012, 90, 410-425.	6.2	239
8	A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. <i>New England Journal of Medicine</i> , 2013, 369, 2304-2312.	27.0	210
9	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	1.3	174
10	Phenotype Standardization for Statin-Induced Myotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 470-476.	4.7	166
11	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	14.3	134
12	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. <i>Pharmacogenomics</i> , 2009, 10, 1687-1695.	1.3	131
13	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. <i>American Journal of Human Genetics</i> , 2011, 88, 6-18.	6.2	122
14	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	2.8	115
15	Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 626-641.	2.4	113
16	Drug-Induced Lipid Changes. <i>Drug Safety</i> , 2001, 24, 443-456.	3.2	100
17	Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1402-1404.	5.6	99
18	Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. <i>European Respiratory Journal</i> , 2018, 51, 1701817.	6.7	98

#	ARTICLE	IF	CITATIONS
19	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	1.3	97
20	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	3.2	97
21	Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. <i>International Journal of Epidemiology</i> , 2016, 45, 1927-1937.	1.9	94
22	Early-life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 971-986.	5.7	90
23	Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. <i>European Respiratory Journal</i> , 2016, 48, 1063-1073.	6.7	89
24	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. <i>European Heart Journal</i> , 2011, 32, 1909-1917.	2.2	86
25	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 735-750.	5.7	83
26	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 957-968.	10.7	83
27	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. <i>European Heart Journal</i> , 2014, 35, 3250-3257.	2.2	81
28	Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing. <i>Annals of Internal Medicine</i> , 2016, 164, 513.	3.9	80
29	Childhood asthma exacerbations and the Arg16 G>T-receptor polymorphism: A meta-analysis stratified by treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 107-113.e5.	2.9	80
30	Breathomics from exhaled volatile organic compounds in pediatric asthma. <i>Pediatric Pulmonology</i> , 2017, 52, 1616-1627.	2.0	78
31	Early life antibiotic use and the risk of asthma and asthma exacerbations in children. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 430-437.	2.6	77
32	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1811-1820.e7.	2.9	74
33	Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. <i>Atherosclerosis</i> , 2002, 163, 213-222.	0.8	71
34	FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1546-1552.	5.7	65
35	Clinical utility of asthma biomarkers: from bench to bedside. <i>Biologics: Targets and Therapy</i> , 2013, 7, 199.	3.2	64
36	Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. <i>Annals of Oncology</i> , 2019, 30, 1660-1666.	1.2	63

#	ARTICLE	IF	CITATIONS
37	Drug-induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	4.7	58
38	Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. <i>Pharmacogenomics Journal</i> , 2017, 17, 386-392.	2.0	56
39	Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. <i>Clinical and Translational Allergy</i> , 2020, 10, 58.	3.2	56
40	Characteristics and treatment regimens across ERS SHARP severe asthma registries. <i>European Respiratory Journal</i> , 2020, 55, 1901163.	6.7	56
41	Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2013, 14, 249-260.	1.3	52
42	Seventeen years of statin pharmacogenetics: a systematic review. <i>Pharmacogenomics</i> , 2016, 17, 163-180.	1.3	52
43	The crosstalk between microbiome and asthma: Exploring associations and challenges. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1067-1086.	2.9	52
44	Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 123-134.	2.9	51
45	Genome-wide association study of inhaled corticosteroid response in admixed children with asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 789-798.	2.9	50
46	Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1064-1072.	1.9	48
47	Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2012, 18, 4526-4537.	7.0	48
48	Arg16 <i>ADRB2</i> genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β_2 -agonists: results of the pacman cohort. <i>Pharmacogenomics</i> , 2013, 14, 1965-1971.	1.3	48
49	A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. <i>Pharmacogenomics Journal</i> , 2016, 16, 231-237.	2.0	47
50	Uncontrolled asthma at age 8: The importance of parental perception towards medication. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 462-468.	2.6	43
51	Pharmacogenetic interactions between <i>ABCB1</i> and <i>SLCO1B1</i> tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. <i>Pharmacogenomics</i> , 2010, 11, 1065-1076.	1.3	42
52	Biomarkers of therapy responsiveness in asthma: pitfalls and promises. <i>Clinical and Experimental Allergy</i> , 2011, 41, 615-629.	2.9	42
53	The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 43-51.	1.5	42
54	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1150-1164.	2.4	42

#	ARTICLE	IF	CITATIONS
55	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	2.2	41
56	Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 451-462.	2.2	39
57	Genetic associations of the response to inhaled corticosteroids in asthma: a systematic review. <i>Clinical and Translational Allergy</i> , 2019, 9, 2.	3.2	39
58	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	3.8	39
59	Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. <i>Atherosclerosis</i> , 2011, 217, 458-464.	0.8	38
60	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.8	38
61	Adherence to and dosing of ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 219-223.	5.7	36
62	Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review. <i>Clinical and Experimental Allergy</i> , 2017, 47, 271-293.	2.9	36
63	Effects of short-term exposures to ultrafine particles near an airport in healthy subjects. <i>Environment International</i> , 2020, 141, 105779.	10.0	36
64	Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 1111.	3.5	35
65	Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR Tj ETQq1 1 0.784314 rgBT /Overlook preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. <i>Pharmacogenetics and Genomics</i> . 2008, 18, 651-656.	1.5	34
66	Statin Prescribing in the Elderly in the Netherlands. <i>Drugs and Aging</i> , 2010, 27, 589-596.	2.7	34
67	Pharmacogenetics of inhaled long-acting beta2-agonists in asthma: A systematic review. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 705-714.	2.6	34
68	Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort. <i>Pharmacogenomics</i> , 2009, 10, 1351-1361.	1.3	33
69	Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. <i>Clinica Chimica Acta</i> , 2011, 412, 2063-2069.	1.1	33
70	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	3.4	33
71	Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. <i>Paediatric Drugs</i> , 2016, 18, 251-260.	3.1	33
72	Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study. <i>European Respiratory Journal</i> , 2020, 55, 1902021.	6.7	32

#	ARTICLE	IF	CITATIONS
73	Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1647-1659.	2.4	31
74	Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 776-785.	2.4	31
75	Treatment response heterogeneity in asthma: the role of genetic variation. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 55-65.	2.5	31
76	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	4.7	31
77	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. <i>Pharmacogenomics</i> , 2017, 18, 931-943.	1.3	30
78	Treating severe asthma: Targeting the IL-5 pathway. <i>Clinical and Experimental Allergy</i> , 2021, 51, 992-1005.	2.9	30
79	Demographic, Environmental, and Genetic Predictors of Metabolic Side Effects of Hydrochlorothiazide Treatment in Hypertensive Subjects. <i>American Journal of Hypertension</i> , 2005, 18, 1077-1083.	2.0	29
80	Interaction between the Gly460Trp α -adducin gene variant and diuretics on the risk of myocardial infarction. <i>Journal of Hypertension</i> , 2009, 27, 61-68.	0.5	29
81	What did we learn from multiple omics studies in asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2129-2145.	5.7	29
82	International severe asthma registry (ISAR): protocol for a global registry. <i>BMC Medical Research Methodology</i> , 2020, 20, 212.	3.1	29
83	Omics for the future in asthma. <i>Seminars in Immunopathology</i> , 2020, 42, 111-126.	6.1	29
84	Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). <i>Acta Cardiologica</i> , 2006, 61, 327-331.	0.9	28
85	Pharmacogenetic analysis of <i>GLCC1</i> in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. <i>Pharmacogenomics</i> , 2014, 15, 799-806.	1.3	28
86	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	1.7	28
87	Impact of Selection Bias on Estimation of Subsequent Event Risk. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	28
88	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. <i>European Respiratory Journal</i> , 2021, 57, 2002042.	6.7	28
89	Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. <i>Pharmacogenomics Journal</i> , 2016, 16, 478-484.	2.0	27
90	Exhaled volatile organic compounds as markers for medication use in asthma. <i>European Respiratory Journal</i> , 2020, 55, 1900544.	6.7	27

#	ARTICLE	IF	CITATIONS
91	Methodological and statistical issues in pharmacogenomics. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 161-166.	2.4	26
92	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010, 11, 989-1002.	1.3	26
93	Childhood asthma in the new omics era: challenges and perspectives. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 155-161.	2.3	26
94	A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 287-293.	1.5	25
95	Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on Serum High-Density Lipoprotein Cholesterol Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2680-2687.	3.6	25
96	Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT) study. <i>American Heart Journal</i> , 2007, 153, 54-58.	2.7	25
97	Characteristics and severity of asthma in children with and without atopic conditions: a cross-sectional study. <i>BMC Pediatrics</i> , 2015, 15, 172.	1.7	25
98	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136324.	2.5	25
99	Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 572-578.	2.3	25
100	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2019, 53, 1900217.	6.7	25
101	The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6627.	4.1	25
102	Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. <i>Pediatric Allergy and Immunology</i> , 2012, 23, 529-536.	2.6	24
103	Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2365-2372.	2.4	24
104	Pharmacogenetics of response to statins: Where do we stand?. <i>Current Atherosclerosis Reports</i> , 2005, 7, 204-208.	4.8	23
105	Determinants of DNA yield and purity collected with buccal cell samples. <i>European Journal of Epidemiology</i> , 2009, 24, 677-682.	5.7	23
106	Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 518-525.	1.5	23
107	The use of pharmacogenomics, epigenomics, and transcriptomics to improve childhood asthma management: Where do we stand?. <i>Pediatric Pulmonology</i> , 2018, 53, 836-845.	2.0	23
108	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	4.7	23

#	ARTICLE	IF	CITATIONS
109	Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 606-614.	3.8	22
110	Breastfeeding is associated with a decreased risk of childhood asthma exacerbations later in life. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 649-654.	2.6	22
111	What do we need to transfer pharmacogenetics findings into the clinic?. <i>Pharmacogenomics</i> , 2018, 19, 589-592.	1.3	22
112	17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2083-2088.	5.7	22
113	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 240.	1.7	22
114	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	3.6	22
115	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1045-1055.	2.9	22
116	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. <i>Pharmacogenomics Journal</i> , 2020, 20, 770-783.	2.0	22
117	Mapping atopic dermatitis and anti-IL-22 response signatures to type 2 low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 89-101.	2.9	22
118	The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 647-653.	5.7	21
119	Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. <i>Atherosclerosis</i> , 2004, 175, 377-379.	0.8	21
120	Biomarkers and asthma management: analysis and potential applications. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 96-108.	2.3	21
121	AsthmaMap: An expert-driven computational representation of disease mechanisms. <i>Clinical and Experimental Allergy</i> , 2018, 48, 916-918.	2.9	21
122	Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , 2019, 10, 364.	2.4	21
123	The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 338-344.	1.5	20
124	Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2489-2497.	3.3	20
125	Early-life antibiotic use and risk of attention-deficit hyperactivity disorder and autism spectrum disorder: results of a discordant twin study. <i>International Journal of Epidemiology</i> , 2021, 50, 475-484.	1.9	20
126	Systems biology in pharmacogenomic research: the way to personalized prescribing?. <i>Pharmacogenomics</i> , 2009, 10, 971-981.	1.3	19

#	ARTICLE	IF	CITATIONS
127	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 3-9.	2.1	19
128	<i>ST13</i> polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1051-1059.	2.9	19
129	The need for precision medicine clinical trials in childhood asthma: rationale and design of the PUFFIN trial. <i>Pharmacogenomics</i> , 2017, 18, 393-401.	1.3	19
130	Breathomics and treatable traits for chronic airway diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 94-100.	2.6	19
131	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	2.5	18
132	Exome Sequencing Reveals Common and Rare Variants in <i>F5</i> Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1195-1202.	4.7	18
133	Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 158-164.	1.4	17
134	Pharmacogenomic insights into treatment and management of statin-induced myopathy. <i>Genome Medicine</i> , 2009, 1, 120.	8.2	17
135	Genetic determinants of response to statins. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 977-983.	1.5	17
136	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012, 13, 1405-1417.	1.3	17
137	Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. <i>Pharmacogenomics</i> , 2013, 14, 869-883.	1.3	17
138	Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1191-1199.	1.9	17
139	Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 152-159.	1.6	17
140	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	3.6	17
141	Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2999-3008.e1.	3.8	17
142	Targeted exhaled breath analysis for detection of <i>Pseudomonas aeruginosa</i> in cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2022, 21, e28-e34.	0.7	17
143	Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use. <i>European Respiratory Journal</i> , 2021, 57, 2003388.	6.7	17
144	High agreement between parental reported inhaled corticosteroid use and pharmacy prescription data. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1199-1203.	1.9	16

#	ARTICLE	IF	CITATIONS
145	Limited agreement between current and long-term asthma control in children: the PACMAN cohort study. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 776-783.	2.6	16
146	Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. <i>Pharmacogenomics Journal</i> , 2011, 11, 72-80.	2.0	16
147	From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 369-375.	2.1	16
148	Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1095-1103.	2.1	16
149	Genetic variation in uncontrolled childhood asthma despite ICS treatment. <i>Pharmacogenomics Journal</i> , 2016, 16, 158-163.	2.0	16
150	Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 112-119.	1.5	16
151	An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 767-772.	3.8	15
152	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 15-17.	4.7	15
153	Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 477-481.	4.7	15
154	Asthma Symptoms in Pediatric Patients: Differences throughout the Seasons. <i>Journal of Asthma</i> , 2011, 48, 694-700.	1.7	14
155	Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 21-28.	1.9	14
156	<i>IL1RL1</i> gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 984-989.	5.7	14
157	High incidence of oral corticosteroids prescriptions in children with asthma in early childhood. <i>Journal of Asthma</i> , 2016, 53, 1012-1017.	1.7	13
158	Markers of Pulmonary Oxygen Toxicity in Hyperbaric Oxygen Therapy Using Exhaled Breath Analysis. <i>Frontiers in Physiology</i> , 2019, 10, 475.	2.8	13
159	Precision medicine in childhood asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 141-147.	2.3	13
160	Genome-wide association studies of exacerbations in children using long-acting beta ₂ -agonists. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1197-1207.	2.6	13
161	Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study. <i>ERJ Open Research</i> , 2021, 7, 00457-2021.	2.6	13
162	Variation at <i>GLCC1</i> and <i>FCER2</i> : one step closer to personalized asthma treatment. <i>Pharmacogenomics</i> , 2012, 13, 243-245.	1.3	12

#	ARTICLE	IF	CITATIONS
163	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 314-320.	4.7	12
164	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4297-4310.	2.4	12
165	The association between antihypertensive drug therapies and plasma lipid levels in the general population. <i>Journal of Human Hypertension</i> , 2001, 15, 701-705.	2.2	11
166	Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 631-636.	1.5	11
167	Asthma Therapy During the First 8 Years of Life: A PIAMA Cohort Study. <i>Journal of Asthma</i> , 2010, 47, 209-213.	1.7	11
168	Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. <i>Pharmacogenomics</i> , 2012, 13, 1239-1245.	1.3	11
169	Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. <i>Osteoporosis International</i> , 2015, 26, 2019-2027.	3.1	11
170	Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. <i>Pediatric Pulmonology</i> , 2016, 51, 1113-1121.	2.0	11
171	Precision medicine in severe pediatric asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 77-83.	2.6	11
172	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
173	Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1238-1243.	5.7	11
174	A System Pharmacology Multi-Omics Approach toward Uncontrolled Pediatric Asthma. <i>Journal of Personalized Medicine</i> , 2021, 11, 484.	2.5	11
175	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. <i>European Respiratory Journal</i> , 2022, 59, 2102603.	6.7	11
176	Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 766-774.	1.5	10
177	No association between <i>CYP3A4*22</i> and statin effectiveness in reducing the risk for myocardial infarction. <i>Pharmacogenomics</i> , 2014, 15, 1471-1477.	1.3	10
178	A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. <i>Pharmacogenomics</i> , 2017, 18, 23-34.	1.3	10
179	Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1336-1342.	2.4	10
180	Blood biomarkers in chronic airways diseases and their role in diagnosis and management. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 361-374.	2.5	10

#	ARTICLE	IF	CITATIONS
181	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 94-101.	3.2	10
182	Variants in genes coding for glutathione S-transferases and asthma outcomes in children. <i>Pharmacogenomics</i> , 2018, 19, 707-713.	1.3	10
183	FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1429-1436.	2.9	10
184	Precision Medicine in Neonates: Future Perspectives for the Lung. <i>Frontiers in Pediatrics</i> , 2020, 8, 586061.	1.9	10
185	Bronchiectasis in Severe Asthma: Does It Make a Difference?. <i>Respiration</i> , 2020, 99, 1136-1144.	2.6	10
186	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. <i>Pharmacogenomics Journal</i> , 2020, 20, 621-628.	2.0	10
187	SHARP: enabling generation of real-world evidence on a pan-European scale to improve the lives of individuals with severe asthma. <i>ERJ Open Research</i> , 2021, 7, 00064-2021.	2.6	10
188	Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 555-563.	2.0	10
189	Reasons for non-response in observational pharmacogenetic research. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 665-671.	1.9	9
190	Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2610-2612.	3.8	9
191	<i>ADRB2</i> Arg16 and the need for collaboration in childhood asthma pharmacogenomics. <i>Pharmacogenomics</i> , 2013, 14, 1937-1939.	1.3	9
192	Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. <i>Pharmacogenomics</i> , 2015, 16, 101-114.	1.3	9
193	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. <i>Pharmacogenomics</i> , 2016, 17, 583-591.	1.3	9
194	Association between C reactive protein and microvascular and macrovascular dysfunction in sub-Saharan Africans with and without diabetes: the RODAM study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001235.	2.8	9
195	Increased day-to-day fluctuations in exhaled breath profiles after a rhinovirus challenge in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2488-2499.	5.7	9
196	Biologicals in childhood severe asthma: the European PERMEABLE survey on the <i>status quo</i>. <i>ERJ Open Research</i> , 2021, 7, 00143-2021.	2.6	9
197	Implementation of pharmacogenetics in clinical practice is challenging. <i>Pharmacogenomics</i> , 2011, 12, 1231-1233.	1.3	8
198	Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 208-214.	1.7	8

#	ARTICLE	IF	CITATIONS
199	Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 422-429.	2.4	8
200	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 465-472.	3.8	8
201	The association between a genetic risk score for allergy and the risk of developing allergies in childhood—Results of the WHISTLER cohort. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 72-77.	2.6	8
202	The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1732-1742.	3.8	8
203	Higher prevalence of peripheral arterial disease in Ghana compared to Ghanaian migrants in Europe: The RODAM study. <i>International Journal of Cardiology</i> , 2020, 305, 127-134.	1.7	8
204	Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000767.	2.8	8
205	Cross-sectional biomarker comparisons in asthma monitoring using a longitudinal design: The eNose premise. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2690-2693.	5.7	8
206	Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103312.	4.4	8
207	Associations of Serum Uric Acid Levels With Macrovascular and Renal Microvascular Dysfunction Among Individuals From Sub-Saharan Africa. <i>JAMA Network Open</i> , 2021, 4, e2128985.	5.9	8
208	Pulmonary Oxygen Toxicity Through Exhaled Breath Markers After Hyperbaric Oxygen Treatment Table 6. <i>Frontiers in Physiology</i> , 2022, 13, .	2.8	8
209	Pharmacogenetics and the Pharmaceutical Industry. <i>Current Pharmaceutical Design</i> , 2010, 16, 238-244.	1.9	7
210	Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. <i>Pharmacogenomics Journal</i> , 2013, 13, 318-324.	2.0	7
211	Adult derived genetic blood pressure scores and blood pressure measured in different body postures in young children. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 320-327.	1.8	7
212	The Influence of Smoking Status on Exhaled Breath Profiles in Asthma and COPD Patients. <i>Molecules</i> , 2021, 26, 1357.	3.8	7
213	Pharmacogenetics of cardiovascular drug therapy. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2009, 6, 55-65.	1.0	7
214	Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 991-999.	1.9	6
215	Asthma medication use in infancy: determinants related to prescription of drug therapy. <i>Family Practice</i> , 2011, 28, 377-384.	1.9	6
216	Evaluation of the effect of genetic variations in <i>GATA-4</i> on the phenprocoumon and acenocoumarol maintenance dose. <i>Pharmacogenomics</i> , 2012, 13, 1917-1923.	1.3	6

#	ARTICLE	IF	CITATIONS
217	Application of routine electronic health record databases for pharmacogenetic research. <i>Journal of Internal Medicine</i> , 2014, 275, 590-604.	6.0	6
218	Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. <i>International Journal of Cardiology</i> , 2015, 201, 644-645.	1.7	6
219	Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. <i>Pediatric Diabetes</i> , 2016, 17, 433-440.	2.9	6
220	Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 116-124.	3.8	6
221	AsthmaMap: An interactive knowledge repository for mechanisms of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 853-856.	2.9	6
222	<i>ADRB2</i> haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1157-1171.	2.9	6
223	Identification of <i>ROBO2</i> as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma. <i>Journal of Personalized Medicine</i> , 2021, 11, 733.	2.5	6
224	Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study. <i>EClinicalMedicine</i> , 2021, 38, 101012.	7.1	6
225	Comparison of microbial composition of cough swabs and sputum for pathogen detection in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 52-60.	0.7	6
226	LTA4H rs2660845 association with montelukast response in early and late-onset asthma. <i>PLoS ONE</i> , 2021, 16, e0257396.	2.5	6
227	Pharmacogenetics in health-care practice. <i>International Journal of Clinical Pharmacy</i> , 2004, 26, 253-255.	1.4	5
228	Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 237-242.	5.0	5
229	<i>CYP2C19</i> and <i>ABCB1</i> genes and individualized treatment with clopidogrel. <i>Pharmacogenomics</i> , 2011, 12, 141-144.	1.3	5
230	Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. <i>Drug Metabolism and Drug Interactions</i> , 2012, 27, 229-234.	0.3	5
231	Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study. <i>Journal of Human Hypertension</i> , 2017, 31, 537-544.	2.2	5
232	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. <i>Pharmacogenomics</i> , 2017, 18, 1143-1153.	1.3	5
233	<i>CKMGluc83Gly</i> Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	5
234	The Impact of Short-Term Exposure to Air Pollution on the Exhaled Breath of Healthy Adults. <i>Sensors</i> , 2021, 21, 2518.	3.8	5

#	ARTICLE	IF	CITATIONS
235	The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation?. <i>Current Molecular Medicine</i> , 2014, 14, 841-848.	1.3	5
236	Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy. <i>ERJ Open Research</i> , 2021, 7, 00381-2021.	2.6	5
237	Assessment of pulmonary oxygen toxicity in special operations forces divers under operational circumstances using exhaled breath analysis. <i>Diving and Hyperbaric Medicine</i> , 2020, 50, 2-8.	0.5	5
238	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	2.5	5
239	Primary ciliary dyskinesia in Volendam: Diagnostic and phenotypic features in patients with a <i>CCDC114</i> mutation. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2022, 190, 89-101.	1.6	5
240	Pharmacogenomic importance of pravastatin. <i>Pharmacogenomics</i> , 2008, 9, 1207-1210.	1.3	4
241	The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 1068-1069.	2.4	4
242	Genotype-guided coumarin dosing: where are we now and where do we need to go next?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 509-522.	3.3	4
243	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 454-464.	3.8	4
244	Detecting Pulmonary Oxygen Toxicity Using eNose Technology and Associations between Electronic Nose and Gas Chromatography-Mass Spectrometry Data. <i>Metabolites</i> , 2019, 9, 286.	2.9	4
245	Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 975.	3.5	4
246	Associations between macrovascular and renal microvascular dysfunction in type 2 diabetes and non-diabetes: the HELIUS study. <i>Microvascular Research</i> , 2021, 136, 104162.	2.5	4
247	Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries. <i>Pediatric Nephrology</i> , 2023, 38, 593-604.	1.7	4
248	Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 375-378.	1.4	3
249	Nonadherence to inhaled corticosteroids: A characteristic of the pediatric obese asthma phenotype?. <i>Pediatric Pulmonology</i> , 2021, 56, 948-956.	2.0	3
250	Association of endopeptidases, involved in SARS-CoV-2 infection, with microbial aggravation in sputum of severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1917-1921.	5.7	3
251	Prediction of asthma in early preschool wheezing by electronic nose analysis. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	2.6	3
252	The potential role of SP-D as an early biomarker of severity of asthma. <i>Journal of Breath Research</i> , 2021, 15, 041001.	3.0	3

#	ARTICLE	IF	CITATIONS
253	Identification of recent exacerbations in COPD patients by electronic nose. ERJ Open Research, 2020, 6, 00307-2020.	2.6	3
254	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. British Journal of Clinical Pharmacology, 2022, , .	2.4	3
255	Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study. BMC Pediatrics, 2013, 13, 94.	1.7	2
256	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. Thrombosis Research, 2015, 136, 94-100.	1.7	2
257	Pharmacogenetics of Coumarin Anticoagulant Therapy. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 307-328.	0.6	2
258	Asthma treatment patterns in Dutch children using medication dispensing data. Pediatric Allergy and Immunology, 2017, 28, 606-608.	2.6	2
259	Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. Drug Metabolism and Personalized Therapy, 2017, 32, 183-190.	0.6	2
260	Effects of age and genetic variations in <i>VKORC1</i> , <i>CYP2C9</i> and <i>CYP3A4</i> on the phenprocoumon dose in pediatric patients. Pharmacogenomics, 2018, 19, 1195-1202.	1.3	2
261	Higher prescription of antidepressants and/or anxiolytics among chronic obstructive pulmonary disease patients. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662096169.	2.6	2
262	Alterations to the urinary metabolome following semi-controlled short exposures to ultrafine particles at a major airport. International Journal of Hygiene and Environmental Health, 2021, 237, 113803.	4.3	2
263	Pharmacogenetics and the Role of the Pharmacist. Journal of Pharmaceutical Finance, Economics and Policy, 2001, 11, 143-150.	0.9	2
264	Exhaled Metabolite Patterns to Identify Recent Asthma Exacerbations. Metabolites, 2021, 11, 872.	2.9	2
265	Are there interactions between the Gly460Trp β -adducin gene variant and the use of diuretics?. Personalized Medicine, 2008, 5, 117-121.	1.5	1
266	Systematic Review of Pharmacogenetic Warfarin Dosing. Journal of General Internal Medicine, 2009, 24, 1171.	2.6	1
267	Asthmatic children that are uncontrolled despite inhaled corticosteroids have a distinct breathprint (the pacman2 study). Clinical and Translational Allergy, 2015, 5, O6.	3.2	1
268	Atopic dermatitis characteristics and medication-use patterns in school-age children with AD and asthma symptoms. Clinical and Experimental Dermatology, 2017, 42, 503-508.	1.3	1
269	Patterns of topical corticosteroids prescriptions in children with asthma. Pediatric Dermatology, 2018, 35, 378-383.	0.9	1
270	C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101870.	2.6	1

#	ARTICLE	IF	CITATIONS
271	Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 985-992.	1.9	1
272	eNose breathprints as surrogate biomarkers for classifying asthma patients by atopy. , 2019, , .		1
273	Pharmacogenetics of Anti-Inflammatory Therapy in Asthma: Corticosteroids and Leukotriene Antagonists. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2010, 9, 267-275.	1.1	1
274	AdDIT Editorial commentâ€”challenges in medication treatment of renal and cardiovascular diseases and risk factors in adolescents with type 1 diabetes. <i>Annals of Translational Medicine</i> , 2018, 6, 193-193.	1.7	1
275	Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis. <i>Frontiers in Genetics</i> , 2020, 11, 570403.	2.3	1
276	Clinical impact of adducin polymorphism. <i>Journal of Hypertension</i> , 2009, 27, 1328-1329.	0.5	0
277	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. <i>American Journal of Human Genetics</i> , 2012, 90, 1116-1117.	6.2	0
278	Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1197-1198.	3.8	0
279	Genomics and Pharmacogenomics of Severe Childhood Asthma. , 2020, , 313-341.		0
280	Immunotherapy for Upper Airway Disease Generates IL-10-Producing KLRG1 <sup>+</sup> ILC2s that are Associated with Clinical Benefit. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0